Tumorschmerztherapie

Arzneimittelkommission der Deutschen Ärzteschaft (2007) Empfehlung zur Therapie von Tumorschmerzen. Arzneiverordnung Praxis 34 [Sonderheft 1] Beck AT, Ward CH, Mendelson M et al. (1961) An inventory for measuring depression. Arch Gen Psychiatry 4: 561–571 Bonica JJ, Wall PD, Melzack R (1985) Textbook of pain. Livingstone, Edinburgh New York Cain DM, Wacnik PW, Eikmeier L et al. (2001) Functional interactions between tumor and peripheral nerve in a model of cancer pain in the mouse. Pain Med 2: 15–23 Caraceni A, Portenoy RK (1999) An international survey of cancer pain characteristics and syndromes. IASP Task Force on Cancer Pain. International Association for the Study of Pain. Pain 82: 263–274 Cleeland CS, Ryan KM (1994) Pain assessment: global use of the Brief Pain Inventory. Ann Acad Med Singapore 23: 129–138 De Conno F, Ripamonti C, Saita L et al. (1995) Role of rectal route in treating cancer pain: a randomized crossover clinical trial of oral versus rectal morphine administration in opioid-naive cancer patients with pain. J Clin Oncol 13: 1004–1008 De Stoutz ND, Bruera E, Suarez-Almazor M (1995) Opioid rotation for toxicity reduction in terminal cancer patients. J Pain Symptom Manage 10: 378–384 Diener KM (1996) Bisphosphonates for controlling pain from metastatic bone disease. Am J Health Syst Pharm 53: 1917–1927 Elsner F, Radbruch L, Sabatowski R et al. (1999) Switching opioids to transdermal fentanyl in a clinical setting. Schmerz 13: 273–278 Fortner BV, Okon TA, Portenoy RK (2002) A survey of pain-related hospitalizations, emergency department visits, and physician office visits reported by cancer patients with and without history of breakthrough pain. J Pain 3: 38–44 Hanks GW, Portenoy RK, Mac Donald N, Forbes K (1998) Difficult pain problems. In: Doyle D, Hanks GW, MacDonald N (eds) Oxford textbook of palliative medicine. Oxford University Press, Oxford, pp 454–477 Honore P, Luger NM, Sabino MA et al. (2000) Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nat Med 6: 521–528; Erratum in: Nat Med (2000) 6: 838 Deutsche Krebsgesellschaft (2002) Leitlinie medikamentöse Schmerztherapie. Interdisziplinäre kurz gefasste Leitlinien der Deutschen Krebsgesellschaft, der Deutschen Gesellschaft für Palliativmedizin, der Deutschen Gesellschaft zum Studium des Schmerzes und der Deutschen Interdisziplinären Vereinigung für Schmerztherapie. Kurzgefasste Interdisziplinäre Leitlinien. 3. Aufl. Lichtor JL, Sevarino FB, Joshi GP et al. (1999) The relative potency of oral transmucosal fentanyl citrate compared with intravenous morphine in the treatment of moderate to severe postoperative pain. Anesth Analg 89: 732–738 Lugo RA, Kern SE (2002) Clinical pharmacokinetics of Morphine. J Pain Palliative Care Pharmacother 16: 5–18 Mantyh PW, Clohisy DR, Koltzenburg M, Hunt SP (2002) Molecular mechanisms of cancer pain. Nat Rev Cancer 2: 201–209 Marinangeli F, Ciccozzi A, Leonardis M et al. (2004) Use of strong opioids in advanced cancer pain: a randomized trial. J Pain Symptom Manage 27: 409–416 Mercadante S, Arcuri E (1998) Breakthrough pain in cancer patients: pathophysiology and treatment. Cancer Treat Rev 24: 425–432 Mercadante S, Radbruch L, Caraceni A et al. (2002) Steering Committee of the European Association for Palliative Care (EAPC) Research Network. Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care. Cancer 94: 832–839 Portenoy RK, Hagen NA (1990) Breakthrough pain: definition, prevalence and characteristics. Pain 41: 273–281 Portenoy RK, Payne R, Coluzzi P et al. (1999) Oral transmucosal Fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study. Pain 79: 303–312 Radbruch L, Loick G, Kiencke P et al. (1999) Validation of the German version of the Brief Pain Inventory. J Pain Symptom Manage 18: 180–187 Radbruch L, Nauck F (2002) European Association for Palliative Care (EAPC): morphine and alternative opioids in cancer pain: the EAPC recommendations. Schmerz 16: 186–193 Radbruch L, Elsner F (2004) Clinical experience with transdermal fentanyl for the treatment of cancer pain in Germany. Keio J Med 53: 23–29 Rees E (2002) The role of oral transmucosal fetanyl citrate in the management of breakthrough cancer pain. Int J Palliat Nurs 8: 304–308 Streisand JB, Varvel JR, Stanski DR et al. (1991) Absorption and bioavailability of oral transmucosal fentanyl citrate. Anesthesiology 75: 223–229 Streisand JB, Busch MA, Egan TD et al. (1998) Dose proportionality and pharmacokinetics of oral transmucosal fentanyl citrate. Anesthesiology 88: 305–309 Svendsen KB, Andersen S, Arnason S et al. (2005) Breakthrough pain in malignant and non-malignant diseases: a review of prevalence, characteristics and mechanisms. Eur J Pain 9: 195–206 Taylor DR, Webster LR, Chun SY et al. (2007) Impact of breakthrough pain on quality of life in patients with chronic, noncancer pain: patient perceptions and effect of treatment with oral transmucosal Fentanyl Citrate (OTFC®, ACTIQ®). Pain Med 8: 281–288 Zeppetella G, O’Doherty CA, Collins S (2000) Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. J Pain Symptom Manage 20: 87–92